Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrimack Pharmaceuticals
With
Sanofi
This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and irinotecan.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
No standard options remaining
Adequate liver and kidney functions
18 years of age or above
You may not be if
History of any secondary active cancer in the last 3 years.
Pregnant or breast feeding
History of severe allergic reactions or contraindications to cetuximab or irinotecan
Clareo Health | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
